Clinical trial
Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk…
NCT00038142 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00038142 |
|---|---|
| Title | Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients |
| Official title | Randomized Phase II Study of Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) With or Without ImmTher for Newly Diagnosed High Risk Ewing's Sarcoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ewing's Sarcoma |
| Intervention type | Biological, Drug |
| Interventions | Vincristine, Doxorubicin, Cyclophosphamide, Dexrazoxane, ImmTher |
| Enrollment | 46 |
| Start date | Nov 1, 1997 |
| Primary completion | Mar 1, 2016 |
| Completion | Mar 1, 2016 |
| First posted | May 30, 2002 |
| Last update posted | Jan 29, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: